Published in final edited form as:

J Autoimmun. 2019 February ; 97: 59–69. doi:10.1016/j.jaut.2018.10.011.

Novel mechanism for estrogen receptor alpha modulation of murine lupus

Melissa A. Cunningham^{1,*}, Mara Lennard Richard¹, Jena R. Wirth¹, Jennifer L. Scott¹, Jackie Eudaly¹, Phil Ruiz³, and Gary S. Gilkeson^{1,2}

¹Medical University of South Carolina, Division of Rheumatology and Immunology, and ²Ralph H. Johnson Veterans Affairs Hospital, Charleston, SC 29425, USA ³University of Miami, School of Medicine, Department of Pathology, 1611 N.W. 12th Ave., Holtz Center, East Tower, Room 2101, Miami, FL 33136, USA

Abstract

Female sex is a risk factor for lupus. Sex hormones, sex chromosomes and hormone receptors are implicated in the pathogenic pathways in lupus. Estrogen receptor alpha (ER α) knockout (KO) mice are used for defining hormone receptor effects in lupus. Prior studies of ER α KO in lupus have conflicting results, likely due to sex hormone levels, different lupus strains and different ER α KO constructs. Our objective was to compare a complete KO of ER α vs. the original functional KO of ER α (expressing a short ER α) on disease expression and immune phenotype, while controlling sex hormone levels. We studied female lupus prone NZM2410 WT and ER α mutant mice. All mice (n=44) were ovariectomized (OVX) for hormonal control. Groups of each genotype were estrogen (E2)-repleted after OVX. We found that OVXed NZM mice expressing the truncated ER α (ER α short) had significantly reduced nephritis and prolonged survival compared to both wildtype and the complete ER α KO (ER α null) mice, but surprisingly only if E2-repleted. ER α null mice were not protected regardless of E2 status. We observed significant differences in splenic B cells and dendritic cells and a decrease in cDC2 (CD11b+CD8-) dendritic cells, without a concomitant decrease in cDC1 (CD11bCD8a+) cells comparing ER α short to ER α null or WT mice. Our data support a protective role for the ER α short protein. ER α short is similar to an endogenously expressed ER α variant (ER α 46). Modulating its expression/activity represents a potential approach for treating female-predominant autoimmune diseases.

* Corresponding author: Melissa Cunningham, 96 Jonathan Lucas Street, Suite 814, MSC637, Charleston, SC 29425, USA, Tel: 843-789-6760 Fax: 843-876-5131 cunnima@musc.edu.

Author Contributions

MC and GG directed the work, contributed to designing the study, and reviewed/interpreted the data. JS helped with data analysis. MC and JW conducted all experiments with help from MLR (related *in vitro* studies), JE (breeding, genotyping, bleeding and urine collection), and PR (pathology). MC and JW prepared the manuscript and figures. GG contributed to manuscript revisions. All authors read and approved the final manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors have declared that no conflict of interest exists.

Keywords

Lupus; hormones; estrogen receptor alpha; dendritic cells

1. Introduction

Nine out of ten patients diagnosed with systemic lupus erythematosus (SLE) are female, thus biologic sex is key in disease susceptibility. The mechanisms underlying the sex disparity in SLE are multifactorial, and likely involve the sex chromosomes, sex hormones and their receptors. There is an established correlation between estrogen and lupus disease expression that is strongly supported by epidemiologic data. Lupus disease incidence is highest during reproductive years, when women are most hormonally active, in contrast to pre-menarche and post-menopause when lupus incidence is lower and the female:male ratio much less profound.

Extensive evidence indicates that estrogen (E2), usually via ER α signaling, has significant immunomodulatory effects on most immune cell types, both developmentally and functionally. Testosterone (T2) and other sex hormones also have known immunomodulatory effects [1–5]. In murine lupus, manipulating sex hormones via classic ovariectomy and castration experiments demonstrated clear roles for E2 and T2 in exacerbating or ameliorating lupus disease expression, respectively [6–8]. However, results from studies where ER α was deleted or disrupted were not as consistent. For example, ER α deficiency in wild-type B6/129 mice resulted in a lupus-like glomerulonephritis [9]. In contrast, targeted ER α disruption in NZM2410 and MRL/lpr female mice ameliorated glomerulonephritis, without decreasing autoantibody production, while in NZB/NZW F1 lupus-prone mice ER α deficiency resulted in attenuation of glomerulonephritis and decreased autoantibody production [10, 11].

Of import, the ER α deficient mice described in all the above reports were studied with intact gonads, which in the setting of ER α disruption, resulted in high serum levels of E2 and T2 in response to elevated GnRH (hypergonadism). Since androgen receptor and estrogen receptor beta are expressed normally in ER α deficient mice, supraphysiologic T2 and E2 represent significant confounders in interpreting these earlier knockout experiments. Recently, we demonstrated that female lupus-prone ER α null mice are in fact not protected from lupus disease expression after ovariectomy indicating the high levels of E2 and T2 might be the mechanism for protection in prior studies of ER α deficiency [12].

Of equal import, although classic ER α endocrine action is absent in the original ER α KO mice [13], there is residual expression of an N-terminally truncated ER α (rather than complete deficiency of ER α) [14]. We refer to this truncated ER α as ER α short. The ER α short is a potential additional confounder in the earlier ER α deficient murine studies done in lupus-prone mice. This short ER α is missing a critical activation domain (AF-1) resulting in, strictly speaking, a functional knockout of ER α for many endocrine endpoints. ER α short mice are infertile and have physiologic deficiencies wherever classic estrogen action via AF-1 is required (ex. reproductive tissues) [13]. However, the ER α protein expressed by these animals retains an intact DNA-binding domain (DBD), cofactor binding domain,

ligand binding domain (LBD) and a second activation domain AF-2, likely preserving some non-classical ER α functions [15]. Thus, mice expressing ER α short may express a murine lupus phenotype different from mice that are ER α null. In this study, we compared ER α short mice to ER α null mice, both on the female NZM2410 lupus-prone background. To control for hypergonadism, test groups of mice were ovariectomized (E2- and T2-depleted), with subsequently E2 repletion (via pellet) or non repletion (placebo pellet).

Unexpectedly, ER α short (missing AF-1) was protective against lupus renal disease, while the ER α null was not. Ovariectomy of mice expressing either ER α short or ER α null resulted in no protection against lupus disease development. The protective effect of the ER α short, but not ER α null, however, was restored by estrogen repletion of the OVXed mice. Thus the mice with the greatest protection against lupus nephritis expressed the ER α short with either endogenous estrogen (ovaries intact) or exogenous estrogen via E2 pellets. These findings indicate there is an active role for ER α short in estrogen-replete mice in modulating disease expression; providing protection not afforded by total deficiency of the full-length ER α . The immune-phenotype of the groups is strikingly different, particularly innate immune cells such as dendritic cells (DCs). Improved understanding of nuclear hormone receptor action may enable targeting specific transcriptional activation domains, as opposed to manipulating hormones, to allow for separation of estrogen effects on different tissues (immune cells versus reproductive tissue, for example). Thus, selective estrogen receptor modulators (SERMs) that are AF-2 agonists, or enhancing expression of endogenous ER α 46 short, may prove to be a therapeutically viable approach to treating lupus and other autoimmune diseases where estrogen may play a pathogenic role.

2. Materials and Methods

2.1 Mice

Mice were maintained at the Ralph H. Johnson VAMC Animal Facility (Charleston, SC). NZM2410 mice were acquired from The Jackson Laboratory (Bar Harbor, ME, USA). ER α KO mice (ER α short) on the C57BL/6 background were a kind gift of Dr. Ken Korach (NIEHS) and are also available commercially (Stock No. 004744, The Jackson Laboratory). Mice carrying this *Esr1^{tm1Ksk}* allele express a truncated form of ER α (ER α short), the result of alternate splicing of the transcript [14]. In contrast, mice carrying the *Esr1^{tm4.2Ksk}* allele (Stock No. 026176, The Jackson Laboratory) are ER α null, and have no tissue responses to estrogen or estrogen receptor alpha activity [16]. All experimental mice (n=44) were female and littermates when possible. All mice were ovariectomized (OVX) pre-disease at 4–8 weeks of age (peri-puberty). Two groups subsequently received 0.25 mg, 90-day sustained release 17 β -estradiol pellet, implanted sub-dermally x 2 occurrences (180d) to ensure continuous systemic E2 levels in adult mice (Innovative Research of America, Sarasota, FL, USA).

2.2 Serum anti-dsDNA, serum estradiol, and serum testosterone

Serum was collected throughout the experiment and at time of sacrifice. Serum anti-dsDNA was measured by ELISA assay, as previously described [10]. Estradiol levels were assessed via ELISA (Calbiotech, San Diego, CA, USA), with an assay sensitivity of 3 pg/ml;

precision: 3.1% (intra-assay), 9.9% (inter-assay). Testosterone serum levels were assessed by radioimmunoassay (RIA) at the University of Virginia Center for Research and Reproduction Ligand Assay and Analysis core.

2.3 Urine protein excretion

Mice were housed in metabolic cages for 24 urine hour collection at 2–4 week intervals starting at 10 weeks of age until sacrifice. To prevent bacterial growth, antibiotics (ampicillin 25ug/mL, gentamicin 50 ug/mL, chloramphenicol 200 ug/mL) were added to the collection tube. After 24 hrs, urine quantity was determined and samples were frozen at –20° for future analysis via mouse albumin ELISA with known standards.

2.4 Spleen and kidney processing and renal pathology

Spleens were harvested and kept in RPMI on ice during processing. The spleens were processed through 40um strainers and depleted of red blood cells with red blood cell lysis buffer (144 mM NH₄Cl and 17 mM Tris, pH 7.6). Spleen cells were washed twice with cold RPMI before being stained for flow cytometry analysis.

One kidney was digested with DNase I (Roche Life Sciences, Indianapolis, Indiana) and collagenase IV (Sigma Aldrich, St. Louis, MO) and PBMCs were isolated using a Percoll gradient (Sigma Aldrich, St. Louis, MO). A second kidney was divided evenly for renal pathology and IHC. Kidney sections were analyzed in a blinded fashion by Dr. Phillip Ruiz (Department of Pathology, University of Miami School of Medicine, Miami, FL) and graded on glomerular hyper-cellularity, segmental mesangial expansion, neutrophils/cell debris, crescent formation, and necrosis. These scores were combined for a total pathology score similar to the Activity Index used in assessing human lupus renal biopsies. Deposition of IgG and complement component C3 was assessed by immunofluorescence after incubating slides with rabbit anti-mouse IgG FITC (Sigma) and sheep anti-mouse C3 FITC (Sigma). IgG and C3 were graded 0–3 for intensity of staining as previously described (17).

2.5 Staining and Flow Cytometry

Spleen cells were stained with Panel I: F4/80-Brilliant violet 421 (1:100), CD19PerCP/Cy5.5 (1:100), CD3-Brilliant violet 605 (1:100), and CD49b-PE (1:400) or Panel II: MHCII-APC (1:200), CD11c-Brilliant violet 605 (1:100), CD8a-Brilliant violet 421 (1:100), CD11b-PE (1:400). Cells were incubated with antibodies for 30 minutes on ice in the dark. All antibodies were purchased from Biolegend (San Diego, CA, USA). Viability was assessed using LIVE/DEAD Fixable Dead Cell stain (Life Technologies, Carlsbad, CA, USA) at a concentration of 50 µl/million cells. Cells were acquired on an LSR Fortessa cell analyzer (BD Biosciences, San Jose, CA, USA) and analysis was performed using FlowJo software (FlowJo LLC, Ashland, Oregon, USA).

2.6 Statistical analysis

Log rank analysis was used to compare trends in animal survival. For all other experiments, depending on whether data was non-parametric or parametric, either Kruskal-Wallis one-way analysis of variance with post-hoc Dunn's multiple comparison test, or ANOVA with post-hoc Dunnett's test were utilized to test for significance when comparing each group to

ER α KO (short) NZM +E2. Standard error of the means was reported where applicable. *p* values ≤ 0.05 were considered significant.

3. Results

3.1 Survival effect of functional ER α knockout (ER α short) vs. deletional ER α knockout (ER α null) in murine lupus

All mice were female and were ovariectomized (OVX). Significant differences in mortality were noted between the groups. Despite OVX, WT NZM2410 animals began to die at 23 weeks with 57% alive by 32 weeks (Figure 1A, black line). This is consistent with known death rates of unmanipulated WT NZM mice previously reported by our group and others [10, 17–19]. Thus, early OVX, and resultant estrogen deficiency alone in WT NZM2410 mice, was not sufficient to provide a robust protective effect. In our earlier study, unmanipulated (gonad-intact) ER α KO NZM mice, referred to in this manuscript as ER α short, had significantly improved renal disease and all survived [20]. In this study, when ER α short NZM mice were ovariectomized (T2- and E2-depleted), they were no longer protected from renal disease and died at a similar rate as WT NZM animals (Figure 1A, blue dashed line). Unexpectedly, however, when the ER α short mice were repleted with estrogen (E2) pellets, disease protection was again present as 100% survived until the pre-determined terminal point of 32 weeks (pink line). This survival is similar to our previous study demonstrating gonad-intact ER α short NZM female mice had a significant survival advantage over WT NZM. These results indicate that E2, but not T2, is required for the protective phenotype observed in ER α short NZM mice.

Consistent with our most recent published study, complete deletion of ER α , referred to as ER α null, was not protective in NZM2410 mice [12]. Survival of OVXed E2-treated ER α null NZM mice at 32 weeks was 57% (Figure 1A, green line), similar to survival of WT NZM. Thus, OVXed ER α short +E2 mice were the only protected group and disease protection was similar to unmanipulated ER α short mice. We conducted pair-wise comparisons of the ER α short +E2 cohort to the other 3 groups. After Bonferroni adjustment, probability of survival in the ER α short +E2 group was significantly greater than the WT and ER α null groups ($p = 0.017$ and 0.019 respectively), and trended toward significance vs. the ER α null +E2 mice (Figure 1A, B). Expressed ER α structures in the individual strains are delineated in Figure 1C.

3.2. Autoimmunity and proteinuria in ER α KO (short) NZM mice vs ER α KO (null) NZM mice

Anti-double stranded DNA (anti-dsDNA) levels were assessed via ELISA at 18 weeks (early stage disease) and at 32 weeks of age (at time of sacrifice). At the early time point, anti-dsDNA levels in WT NZM mice were higher than all other groups, although only significantly increased compared to ER α short mice (Figure 2A). Since all mice were OVXed, including WT mice, and had near undetectable levels of serum T2 and E2 (Supplemental Figure 1), the results suggest that lack of sex hormones does not protect against autoantibody development in the NZM2410 model. By 32 weeks, anti-dsDNA levels were elevated in all groups with no significant differences observed (Figure 2B), suggesting

that neither E2 or T2 deficiency, nor differences in ER α expression ultimately impact development of autoantibodies in this model, although they may change the timing of such. This is again consistent with our previous results in unmanipulated ER α short NZM mice in which serum autoantibody levels were elevated, not reduced compared to WT NZM2410 mice, despite significant improvement in other lupus disease parameters.

Urine protein levels (24h collection) were assessed using albumin ELISA. In general, all groups had low levels of proteinuria at 18 weeks (Figure 2C). However, by 32 weeks (terminal urine collection), E2-treated ER α short mice had significantly less proteinuria compared to E2-treated ER α null mice (Figure 2D). This protective effect was not due to differences in T2, since mice had nearly undetectable levels of T2 following OVX. Nor was it due to difference in E2 levels, which were not different between the 2 E2-treated groups (Supplemental Figure 1). The effect was also not due to differences in levels of ER β or androgen receptor (AR), since expression of these nuclear hormone receptors is intact in all 4 groups and previously shown to be largely unchanged in ER α deficient mice [21]. These data further support the hypothesis that lupus prone mice expressing ER α short, but not ER α null, are protected from kidney disease, and the effect requires E2.

3.3 Effects of short ER α variant expression on renal histopathology, C3 and IgG Deposition in NZM2410 Mice

Renal pathology scores, range: 0–18, were determined by a blinded pathologist using H&E stained kidney samples. The most common changes contributing to an elevated glomerular score in WT NZM mice were hypercellularity, mesangial expansion, membrane thickening, and focal segmental glomerular sclerosis. Despite early OVX of all mice, WT NZM mice developed diseased glomeruli with moderate-severe IgG deposition, whereas ER α short +E2 mice had normal glomeruli with mild-moderate IgG deposition (Figure 3 A,B). ER α short mice that were OVXed without E2-repletion were not similarly protected, but rather had disease similar to WT animals. ER α null mice developed proliferative renal disease similar to WT NZM (whether receiving E2 or not). These results are thus highly consistent with the proteinuria data; only ER α short +E2 mice were protected. Deposition of C3 and IgG, markers of kidney involvement in lupus disease, was determined by immunofluorescence. Samples were graded on a 0–3 scale by a blinded scorer. While the ER α short +E2 treatment group trended toward lower deposition scores overall, only the IgG deposition was significantly lower compared to WT NZM mice after accounting for multiple comparisons. Both ER α short +E2 and ER α null +E2 groups trended towards lower C3 and IgG scores suggesting that perhaps E2 plays a separate role in immune complex formation/deposition that does not require an intact full-length ER α , similar to the impact on autoantibody production. These data are in agreement with our previous study in which unOVXed ER α short mice had improved renal scores, but no significant reduction in either autoantibody formation or immune complex deposition, suggesting that the local inflammatory responses to immune complex deposition in the kidney are more prominently impacted than other parameters of systemic autoimmunity by ER α .

As in human lupus, the renal scoring system is based on glomerular pathology, but we also assessed chronic inflammation and fibrosis in the tubulointerstitium (TI). NZM mice had

concomitant disease in the TI that paralleled the severity of disease in the glomerulus, with reduced severity in the ER α short +E2 mice compared with the other groups (data not shown). We also performed flow cytometry analysis on single cell suspensions prepared from whole kidneys, which provided additional supporting evidence for decreased chronic inflammation in ER α short +E2 mice, which had significantly fewer MHCII⁺, CD11c⁺, and CD19⁺ cells, and trends toward reduced percent of CD3⁺ and CD49b⁺ cells (supplemental data, Table S1, S2). There was also a trend towards reduced percent of cDC2s (CD8 α -CD11b⁺ DCs) from kidneys. cDC1s (CD8 α +CD11b⁻) were exceedingly rare (supplemental figure 4), consistent with previous data in other lupus-prone mice (NZB/W) demonstrating a lack of CD8 α + DCs as a subpopulation of renal mononuclear phagocytes [22]. There was no significant change in F4/80⁺ cells. In summary, only ER α short +E2 mice had significantly lower renal pathology scores (all <3) and proteinuria and 100% survival rate, as well as reduced local inflammation by flow cytometric analysis of kidney immune cells.

3.4 Spleen cell subsets in ER α KO (short) NZM vs ER α KO (null) NZM mice

Total number of spleen cells and spleen weight were variable within the cohorts with no significant differences observed between groups, although there was a trend towards reduced spleen counts in ER α short +E2 mice (Figure 4A). Although some spleens were enlarged, there was no association between spleen weight and survival or renal disease. There was a trend towards smaller spleens in ER α short NZM mice regardless of E2 status.

Spleen cells were isolated and stained with either of two panels for flow cytometry analysis. Standard markers were used to look for changes in spleen composition of macrophages, B cells, T cells, NK-T cells, NK cells, and DC subsets, as outlined in methods. Gates were set on FMO (Fluorescence Minus One) and the gating strategy is outlined in Figure 4B. There was a small, but statistically significant decrease, in mature macrophages, as indicated by F4/80 positivity, in spleens from ER α short +E2 mice compared with ER α null +E2 mice (Figure 4C). Consistent with the kidney cellular results, there was also a trend towards reduced percent and absolute number of B cells in spleen of ER α short +E2 mice compared to the other groups, and this reduction was statistically significant compared with WT NZM (both percent and absolute number). There were no significant differences in either absolute numbers (Figure 4C) or percent (data not shown) of T cells, NK-T cells, or NK cells among the different groups of mice.

Given the compelling evidence for estrogen and ER α impacts on dendritic cell (DC) development and function (reviewed in [23]), including our previous reports of ER α modulation of TLR-stimulated pathways in both conventional and plasmacytoid DCs in lupus prone mice [24–26], we hypothesized that DCs would be most differentially affected in ER α deficient mice. A second flow cytometry panel was utilized to look at antigen presenting cells with markers to assess conventional DCs in the spleen: MHCII, CD11c, CD11b, and CD8 α . There was a trend towards reduced absolute number (but not percent) of MHCII⁺ cells in ER α short mice regardless of E2 repletion, but a significant reduction in absolute number of MHCII⁺ cells and MHCII⁺CD11c⁺ cells was observed between ER α short +E2 mice vs ER α null +E2 mice (Figure 5B). As in nonautoimmune mice, ER α signaling was dispensable for cDC development (absolute numbers) [27], since all mice were

either missing E2 (all OVXed) and/or a full length ER α . Interestingly, in the ER α short +E2 mice only, there was a significant decrease in cDC2 cells (MHCII+CD11c+CD8a-CD11b+), a DC subset that specializes in the presentation of antigen to CD4+ T cells and favors polarization towards Th2 or Th17 responses [28, 29]. There was no concomitant change in cDC1 cells (MHCII+CD11c+CD8a+CD11b-). An overall decrease in the number of mature, activated DCs in spleen of the ER α short +E2 group, also seen in the kidney, may partially explain the protected phenotype in this group. The short ER α (functionally an AF-1 mutant), in the setting of estrogen, impacts DC development more so than the presence or absence of full length ER α in this lupus model, in agreement with similar studies in non-autoimmune mice [27]. We additionally show for the first time that this short ER α plays a role in the development of specific DC subsets that likely impact lupus disease expression.

3.5 Flt3L-cultured BMDCs from ER α KO (short) NZM +E2 are profoundly impacted and differ in CD8a and CD11b positivity

Given the differences in cDC subsets observed in spleens of ER α short NZM mice, we looked at more proximal DC development by isolating bone marrow from femurs of NZM mice and culturing them *ex vivo* in Flt3L to enrich for DCs. In nonautoimmune mice, E2-ER α signaling inhibits the development of pDCs and cDCs in Flt3L-driven BM cultures [30]. In a separate study, the developmental effect on pDCs was dependent on ER α AF-1, while E2-ER α effects on cDCs were limited to functional endpoints (ex. activation markers, TLR responses), rather than reduction in absolute number [27].

In NZM lupus-prone mice, we found that BM yield (Supplemental figure 3) and percent of MHCII+CD11c+ cells were both profoundly decreased in ER α short +E2 mice, with a significant difference in the percent of DCs yielded under these culture conditions (Figure 6A, B). Similar to what we observed in spleens of the ER α short +E2 mice, Flt3L-cultured BMDCs also differed in DC subset numbers, with a significant reduction in CD11b+ DCs (cDC2s) and a concomitant increase in CD11b-CD8a+ cDC1s. Together these data suggest that both number and type of DC are impacted by E2 and ER α in lupus mice. Of note, all mice were OVXed, including WT, thus were missing either E2, or a full length ER α , or both. Consequently, these data suggest that in the presence of E2, the short ER α (AF-1 mutant) may actively suppress expansion of CD11b+ (inflammatory) DCs, without similarly suppressing (or may even promote) CD8a+CD11b- DCs, since the effect of the liganded short ER α differs from both unliganded short ER α and E2-treated ER α null mice.

4. Discussion

To determine the impact of sex hormones and ER α deletion on murine lupus, we investigated the effect of ovariectomy (OVX) +/- estradiol (E2) repletion on lupus disease phenotype in NZM2410 mice. We compared ER α short (original Korach ER α KO) female mice, vs. ER α null (a total body ER α deletion mutant, also kind gift of Korach Lab). Unlike the NZM lupus prone mice with ER α null, which we recently described [12], ER α short mice were protected from lupus glomerulonephritis after OVX, if they were E2-repleted. ER α null mice were not protected regardless of estrogen repletion. Together with our previous work, these results support our working hypothesis that expression of the short

form of ER α (that lacks AF-1) confers protection, and this effect requires E2. OVXed ER α short +E2 female mice lived significantly longer (all survived until the pre-determined sacrifice endpoint) vs. all other groups of female mice studied. This prolonged survival is similar to our previous report of the protective effect of ER α short in non-OVXed NZM2410 and MRL/lpr mice compared to wildtype [10].

Our current results rule out elevated testosterone as the protective effect in ER α short mice, since all animals were OVXed to control for hypergonadism. Without OVX, ER α deficiency leads to hypergonadism with resultant aberrantly high serum testosterone and estrogen levels in both ER α short and ER α null females. These elevated levels of E2 and/or T2 were a potential confounder of previous experiments using ER α KO mice in lupus models. Supplemental figure 1 plots the elevated levels of E2 and T2 seen in un-manipulated female ER α KO mice and shows the normalized/reduced levels of T2 and E2 after OVX in mice from this study. As an additional control, the impact of E2 deficiency was assessed in WT and ER α short OVXed animals that were not E2-treated. In previous studies, elevated E2 levels seen in ER α KO animals may also be a confounder since high E2 levels could 1) act via an intact ER β receptor to exert effects and/or 2) impact levels of other hormones such as prolactin which have immunomodulatory potential. We previously demonstrated that complete ER α deficiency is not directly protective in murine lupus [12]. OVXed vs. nonOVXed ER α null mice also have disparate disease states and immune phenotypes, likely due to aforementioned hypergonadism and elevated T2. Since all animals in this study were OVXed, our data demonstrates that neither E2 or T2 levels alone can explain the profound differences between ER α short +E2 mice and the other groups, particularly the ER α null +E2 mice, which have the same hormone profile, but were not protected. The protective effect is also not due to other intact nuclear hormone receptors (ER β , AR, etc.), since these too are the same between ER α null +E2 and ER α short +E2 mice. Finally, and of equal import, the data demonstrate the requirement for E2 ligand in the protective effect, since both the truncated receptor *and* E2 are needed for the phenotype.

This study is the first report demonstrating a ligand-dependent protective role for a truncated ER α (AF-1 mutant) in murine lupus, after correcting for the confounder of aberrant hormone levels. Given that there exists an endogenously expressed short ER α variant in mice and humans, ER α 46, that also lacks AF-1, these findings suggest that ER α 46 may have an immune modulatory role, either directly or as a competitive inhibitor of full length ER α 66. Thus, there is the possibility of targeting ER α by increasing ER α 46 activity with a selective estrogen receptor modulator (SERM) for treating female-predominant autoimmune diseases. Pharmacological activation or inhibition of ER α already provides the foundation for therapeutic interventions in breast cancer and osteoporosis, for example. Since E2 was required for protection in this model, future work will focus on E2-induced expression levels of ER α variants in murine and human lupus, as well as possible effects of AF-2 mediated transcriptional activation in the setting of AF-1 absence. The appropriate use and efficacy of SERMs relies on our ability to understand the molecular actions of ER α in individual tissues and celltypes so we may uncouple beneficial effects from detrimental ones. Additional important studies include the factors that control expression of ER α 46 versus ER α 66 as perhaps increasing expression of ER α 46 in immune cells may also be therapeutic.

Classic E2-dependent ER α activation involves both AF-1 and AF-2 interaction, but these activation domains can also independently activate transcription in a cell-type specific manner. For example, AF-1 is not required for E2-mediated vascular or bone protection, but is required for reproductive function and proliferation of uterine epithelial cells, as well as breast cancer cells [31–33]. It is additionally known that AF-1 and AF-2 transactivation depends on the differentiation stage of the cell. Specifically, while transcriptional activity of ER α relies on AF-1 in most estrogen target cell types, the less differentiated the cell, the less it mediates transcription through AF-1 [34]. AF-1 also appears to be a requirement for maturation of some immune cells. Seillet *et al.* demonstrated a differential requirement for ER α AF-1 in the development of different DC subsets *in vitro* when cultured in GM-CSF [27]. Specifically, AF-1 was required for functionally competent classic and plasmacytoid DCs. This was of great interest to us, since we previously showed a reduction in bone marrow-derived dendritic cell number in lupus-prone ER α short female mice, as well as a blunted response of these cells to TLR7/9 stimulation [24]. Thus, at some critical point in DC development (hypothesized to be at the macrophage-DC progenitor or common DC progenitor stage), absence of either E2 or an AF-1-intact ER α impedes development of a mature/activated (i.e. inflammatory) DC phenotype resulting in less TLR responsiveness. Conversely, in a lupus vulnerable genotype, the presence of E2 and an imbalance/shortage of protective ER α variants may promote maturation/activation of dysregulated DCs with heightened TLR responsiveness. Consistent with this, our protected lupus-prone ER α short +E2 mice, which express no full length ER α , have fewer mature inflammatory-type (MHCII +CD11c+CD11b+) DCs in the spleen and from Flt3L-cultured BM. This premise also makes sense within the framework of murine and human lupus, where DCs are known to be inappropriately over-activated and thus less capable of regulating autoreactive B cells [35].

While this study focused on controlling for aberrant sex hormone levels, as well as different ER α constructs, there were study design limitations to include 1) the length of time necessary to breed female ER α mutant mice for study participation in addition to the length of time to develop significant disease in this model (32 week endpoint). This resulted in inter-experimental time lapse between flow experiments (done variably on sacrifice days as animals came of age or became ill). To the extent possible, interexperimental variables were minimized (antibody lots, consistent voltages on flow machine, etc). Where samples could be batch-processed (ex. anti-dsDNA ELISA, albumin ELISA, all histology), they were. An additional variable/limitation was the use of estradiol pellets for E2 replacement. Given the length of time to maintain E2-repletion (~6 months), daily E2 injections were not feasible due to time/labor constraints. We chose E2 pellets implanted subcutaneously instead of surgical implant of silastic tubing with E2 (both slow-release). Although both methods are validated for achieving stable plasma estradiol levels in murine studies, data support a reduced spike in serum E2 levels in the first week after pellet implant (vs. silastic tubing) [36]. The variability in serum estradiol levels seen in our E2-repleted mice is likely due to the estradiol assay itself. Although we used the estradiol ELISA method that is the gold standard at The Ligand Assay and Analysis Core of the Center for Research in Reproduction (CRR) at UVA, estradiol ELISAs, like IFN α ELISAs, have sensitivity and specificity issues [37]. We, and other investigators, have been working to optimize these assays over the years, however problems remain. Thus, we currently use serum estradiol levels *only* to demonstrate

that we have corrected the supraphysiologic E2 levels that exist in female mice with hypergonadism (after OVX), as well as to confirm that mice with 17 β -estradiol pellet-treatment have not been overdosed with supraphysiologic levels. For these purposes, the results of the serum E2 levels are still quite informative (similarly with the T2).

In summary, despite myriad studies of estrogen effects on different cell types in lupus, we still have limited understanding of the molecular mechanisms of action governing ER α and other nuclear hormone receptors in normal immunity and autoimmunity. Hormones clearly have variable effects on B, T, and dendritic cell functions [38]. Small clinical trials and case series have suggested benefits of androgens or known selective estrogen receptor modulators (SERMs) in lupus, but these are not well tolerated (ex. DHEA and fulvestrant, respectively) [39, 40]. Other trials confirmed the safety of estrogen-containing oral contraceptives, although hormone-replacement therapy induced mild flares in post-menopausal lupus patients [41, 42]. Overall, however, we have not progressed our understanding of sex effects on disease to the benefit of patients. The current study is the first to describe potential benefits of a short ER α (similar to endogenous ER α 46 derived via an alternative transcription start site) in lupus. Presence alone of the short ER α , without ER α 66, significantly impacts immune cells, particularly innate immune cells, in the NZM2410 lupus model, and profoundly reduces renal disease expression. Thus ER α 46, and perhaps other endogenous ER α variants, represent a potential therapeutic target based on its apparent potential anti-inflammatory effects. Future studies are needed to determine whether imbalance of ER α variants plays a role in disease, and to identify the central regulatory functions of ER α 46 (vs. the classic full-length ER α 66) on gene targets, as well as AF-1- vs. AF-2-mediated transcription. In addition, given that most autoimmune diseases are more prevalent in women, these studies may help identify the mechanisms of estrogen and ER α action that lead to increased female risk in autoimmunity.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors wish to thank our long-time collaborator Ken Korach at NIEHS for both ER α KO strains of mice as well as his insight through the years. We would also like to acknowledge Erin Collins, Osama Naga, and Ivan Molano for help with experimental troubleshooting and ELISA assistance. We would like to express our thanks to Adam Soloff in the Cell Evaluation & Therapy Shared Resource at the Hollings Cancer Center for help with flow cytometry set-up and helping us to produce high quality flow data for reproducibility.

Funding: This publication was supported by The South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, NIH/NCATS Grant number **TR001452** and **KL2 TR000060**; and a VA Medical Research Service Merit Award **1I01BX000470-01**. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCRR. Supported in part by the Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, Medical University of South Carolina (**P30 CA138313**).

References

- [1]. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. *Lupus*, 2004;13:635–8. [PubMed: 15485092]

- [2]. Grossman CJ. Interactions between the gonadal steroids and the immune system. *Science*, 1985;227:257–61. [PubMed: 3871252]
- [3]. Foo YZ, Nakagawa S, Rhodes G, Simmons LW. The effects of sex hormones on immune function: a meta-analysis. *Biol Rev Camb Philos Soc*, 2017;92:551–71. [PubMed: 26800512]
- [4]. Ansar Ahmed S, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. *Am J Pathol*, 1985;121:531–51. [PubMed: 3907369]
- [5]. Trigunaite A, Dimo J, Jorgensen TN. Suppressive effects of androgens on the immune system. *Cell Immunol*, 2015;294:87–94. [PubMed: 25708485]
- [6]. Talal N. Natural history of murine lupus. Modulation by sex hormones. *Arthritis Rheum*, 1978;21:S58–63. [PubMed: 352366]
- [7]. Roubinian JR, Papoian R, Talal N. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. *J Clin Invest*, 1977;59:1066–70. [PubMed: 864003]
- [8]. Talal N. Sex steroid hormones and systemic lupus erythematosus. *Arthritis Rheum*, 1981;24:1054–6. [PubMed: 6974552]
- [9]. Shim GJ, Kis LL, Warner M, Gustafsson JA. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. *Proc Natl Acad Sci U S A*, 2004;101:1720–4. [PubMed: 14745006]
- [10]. Svenson JL, Eudaly J, Ruiz P, Korach KS, Gilkeson GS. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. *Clinical immunology*, 2008;128:259–68. [PubMed: 18514033]
- [11]. Bynote KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. *Genes Immun*, 2008;9:137–52. [PubMed: 18200028]
- [12]. Scott JL, Wirth JR, Eudaly J, Ruiz P, Cunningham MA. Complete knockout of estrogen receptor alpha is not directly protective in murine lupus. *Clin Immunol*, 2017;183:132–41. [PubMed: 28822833]
- [13]. Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS et al. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. *Recent Prog Horm Res*, 1996;51:159–86; discussion 86–8. [PubMed: 8701078]
- [14]. Kos M, Denger S, Reid G, Korach KS, Gannon F. Down but not out? A novel protein isoform of the estrogen receptor alpha is expressed in the estrogen receptor alpha knockout mouse. *J Mol Endocrinol*, 2002;29:281–6. [PubMed: 12459030]
- [15]. Arnal JF, Fontaine C, Abot A, Valera MC, Laurell H, Gourdy P et al. Lessons from the dissection of the activation functions (AF-1 and AF-2) of the estrogen receptor alpha in vivo. *Steroids*, 2013;78:576–82. [PubMed: 23200732]
- [16]. Hewitt SC, Kissling GE, Fieselman KE, Jayes FL, Gerrish KE, Korach KS. Biological and biochemical consequences of global deletion of exon 3 from the ER alpha gene. *FASEB J*, 2010;24:4660–7. [PubMed: 20667977]
- [17]. Cunningham MA, Wirth JR, Scott JL, Eudaly J, Collins EL, Gilkeson GS. Early Ovariectomy Results in Reduced Numbers of CD11c+/CD11b+ Spleen Cells and Impacts Disease Expression in Murine Lupus. *Front Immunol*, 2016;7:31. [PubMed: 26913030]
- [18]. Morel L, Croker BP, Blenman KR, Mohan C, Huang G, Gilkeson G et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. *Proc Natl Acad Sci U S A*, 2000;97:6670–5. [PubMed: 10841565]
- [19]. Mathenia J, Reyes-Cortes E, Williams S, Molano I, Ruiz P, Watson DK et al. Impact of Fli-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice. *Clin Exp Immunol*, 2010;162:362–71. [PubMed: 20731671]
- [20]. Svenson JL, Eudaly J, Ruiz P, Korach KS, Gilkeson GS. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. *Clin Immunol*, 2008;128:259–68. [PubMed: 18514033]
- [21]. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger

- ribonucleic acid in the wild-type and ERalpha-knockout mouse. *Endocrinology*, 1997;138:4613–21. [PubMed: 9348186]
- [22]. Sahu R, Bethunaickan R, Singh S, Davidson A. Structure and function of renal macrophages and dendritic cells from lupus-prone mice. *Arthritis Rheumatol*, 2014;66:1596–607. [PubMed: 24866269]
- [23]. Laffont S, Seillet C, Guery JC. Estrogen Receptor-Dependent Regulation of Dendritic Cell Development and Function. *Front Immunol*, 2017;8:108. [PubMed: 28239379]
- [24]. Cunningham MA, Naga OS, Eudaly JG, Scott JL, Gilkeson GS. Estrogen receptor alpha modulates Toll-like receptor signaling in murine lupus. *Clin Immunol*, 2012;144:1–12. [PubMed: 22659029]
- [25]. Scott JL, Cunningham MA, Naga OS, Wirth JR, Eudaly JG, Gilkeson GS. Estrogen Receptor alpha Deficiency Modulates TLR Ligand-Mediated PDC-TREM Expression in Plasmacytoid Dendritic Cells in Lupus-Prone Mice. *J Immunol*, 2015;195:5561–71. [PubMed: 26553076]
- [26]. Scott JL, Wirth JR, Eudaly JG, Gilkeson GS, Cunningham MA. Plasmacytoid dendritic cell distribution and maturation are altered in lupus prone mice prior to the onset of clinical disease. *Clin Immunol*, 2016;175:109–14. [PubMed: 28041989]
- [27]. Seillet C, Rouquie N, Foulon E, Douin-Echinard V, Krust A, Chambon P et al. Estradiol promotes functional responses in inflammatory and steady-state dendritic cells through differential requirement for activation function-1 of estrogen receptor alpha. *J Immunol*, 2013;190:5459–70. [PubMed: 23626011]
- [28]. Schlitzer A, Ginhoux F. Organization of the mouse and human DC network. *Curr Opin Immunol*, 2014;26:90–9. [PubMed: 24556405]
- [29]. Schlitzer A, McGovern N, Ginhoux F. Dendritic cells and monocyte-derived cells: Two complementary and integrated functional systems. *Semin Cell Dev Biol*, 2015;41:9–22. [PubMed: 25957517]
- [30]. Carreras E, Turner S, Paharkova-Vatchkova V, Mao A, Dascher C, Kovats S. Estradiol acts directly on bone marrow myeloid progenitors to differentially regulate GM-CSF or Flt3 ligand-mediated dendritic cell differentiation. *J Immunol*, 2008;180:727–38. [PubMed: 18178810]
- [31]. Billon-Gales A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, Flouriot G et al. The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. *Proc Natl Acad Sci U S A*, 2009;106:2053–8. [PubMed: 19188600]
- [32]. Fontaine C, Abot A, Billon-Gales A, Flouriot G, Berges H, Grunenwald E et al. Tamoxifen elicits atheroprotection through estrogen receptor alpha AF-1 but does not accelerate reendothelialization. *Am J Pathol*, 2013;183:304–12. [PubMed: 23669343]
- [33]. Borjesson AE, Windahl SH, Lagerquist MK, Engdahl C, Frenkel B, Moverare-Skrtic S et al. Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. *Proc Natl Acad Sci U S A*, 2011;108:6288–93. [PubMed: 21444817]
- [34]. Merot Y, Metivier R, Penot G, Manu D, Saligaut C, Gannon F et al. The relative contribution exerted by AF-1 and AF-2 transactivation functions in estrogen receptor alpha transcriptional activity depends upon the differentiation stage of the cell. *J Biol Chem*, 2004;279:26184–91. [PubMed: 15078875]
- [35]. Seitz HM, Matsushima GK. Dendritic cells in systemic lupus erythematosus. *Int Rev Immunol*, 2010;29:184–209. [PubMed: 20367140]
- [36]. Oetken K. The Effects of Different Estradiol Delivery Methods on Plasma Estradiol Levels in Mice Department of Nutrition and Food Science: Texas A&M University; 2014.
- [37]. Haisenleder DJ, Schoenfelder AH, Marcinko ES, Geddis LM, Marshall JC. Estimation of estradiol in mouse serum samples: evaluation of commercial estradiol immunoassays. *Endocrinology*, 2011;152:4443–7. [PubMed: 21933867]
- [38]. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. *Clin Rev Allergy Immunol*, 2011;40:66–73. [PubMed: 20352526]
- [39]. van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. *Lupus*, 1999;8:181–7. [PubMed: 10342710]

- [40]. Abdou NI, Rider V, Greenwell C, Li X, Kimler BF. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebocontrolled trial. *J Rheumatol*, 2008;35:797. [PubMed: 18381791]
- [41]. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med*, 2005;142:953–62. [PubMed: 15968009]
- [42]. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR et al. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med*, 2005;353:2550–8 [PubMed: 16354891]

Highlights

- NZM2410 mice expressing an ER α short variant are protected from glomerulonephritis
- The protective effect of ER α “short” requires estrogen, but not testosterone
- B cells and dendritic cells are reduced in NZM mice expressing the ER α short variant
- CD8+CD11b- (cDC1s) are increased vs. CD8 α -CD11b+ (cDC2s) cells in NZM ER α short mice

Figure 1: Survival of ERαKO NZM2410 mice.

All mice were female and underwent ovariectomy (OVX). A) Kaplan-Meier curve: 100% of ERα short +E2 mice survived to the 32 week terminal point, whereas survival in other cohorts was 30–57% at 32 weeks. B) Global pvalue of differences among all 4 groups (using a log-rank test) was 0.072. Pair-wise comparisons of ERα short +E2 animals to each of the other 3 groups (using a Bonferroni adjusted p-value), resulted in a significantly increased probability of survival in the ERα short +E2 group in comparison with WT and untreated ERα short groups ($p = 0.017$ and 0.019 respectively), and trended toward significance vs. the ERα null +E2 mice.

Figure 2: Anti-double stranded DNA and proteinuria in ERαKO NZM2410 mice.

A) AntidsDNA levels as measured by ELISA were elevated in WT NZM mice by 18 weeks, and were significantly higher than in ERα short mice. B) By 32 weeks (or at sacrifice), serum anti-dsDNA antibody levels were high in all groups with no significant differences. C) At 18 weeks, no significant proteinuria, as measured by 24h urine collection on metabolic cages, was noted in any group. D) ERα short +E2 mice maintained low or undetectable levels of proteinuria throughout the study and had significantly less proteinuria compared to untreated ERα short and ERαKO null +E2 mice at the terminal time point.

Figure 3: Renal pathology scores, C3 and IgG Deposition in ERαKO NZM2410 mice.

A) Histopathology was scored by a blinded pathologist based on multiple parameters including glomerular hypercellularity, segmental mesangial expansion, membrane thickening, neutrophils/cell debris, crescent formation and focal segmental glomerular sclerosis. ERα short +E2 mice had very low renal pathology scores (<3), which was significantly lower than the other treatment groups. Other treatment groups were varied, with animals having either high (≥ 15) or low scores (<5), indicating few animals with moderate disease. B) C3 and IgG deposition were assessed via immunofluorescence after incubating slides with sheep anti-mouse C3 or rabbit anti-mouse IgG antibodies. Slides were scored on a 0–3 scale by a blinded investigator. WT NZM and untreated ERα short mice had both diseased glomeruli and moderate to high C3 and IgG deposition. E2-treated ERα short and ERα null mice had mild to moderate IgG deposition.

Figure 4: Spleen cell flow cytometry analysis in ER α KO NZM2410 mice, Panel 1.

All mice were female and were ovariectomized. A) Spleen counts and weights were variable among treatment groups with no significant differences. B) Images are representative of the flow cytometry analysis strategy with gates set on FMO. C) Results are summarized in graphs showing a small but significant reduction in absolute numbers of F4/80+ spleen cells in ER α short +E2 vs. ER α KO null +E2 mice, as well as a significant reduction in absolute numbers of CD19+ spleen cells in ER α KO short +E2 vs. WT NZM. Although there were trends towards other differences, there were overall not significant differences among the 4 groups with regard to spleen T cells, NK-T cells or NK cells.